{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:07:41Z","timestamp":1788869261268,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cllc.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:43:07Z","timestamp":1784763787000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Efficacy and Safety of Icotinib as Adjuvant Therapy for Resected Stage IA Lung Adenocarcinoma: A Real-world Study"],"prefix":"10.1016","volume":"27","author":[{"given":"Si-Sheng","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Qi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2026.07.006_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.cllc.2026.07.006_bib0002","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/JTO.0b013e31819cce50","article-title":"Lymph node dissection for lung cancer: significance, strategy, and technique","volume":"4","author":"Watanabe","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.006_bib0003","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","article-title":"The eighth edition lung cancer stage classification","volume":"151","author":"Detterbeck","year":"2017","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.cllc.2026.07.006_bib0004","first-page":"242","article-title":"Recurrence after surgery in patients with NSCLC","volume":"3","author":"Uramoto","year":"2014","journal-title":"Transl Lung Cancer Res"},{"issue":"21","key":"10.1016\/j.cllc.2026.07.006_bib0005","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.07.006_bib0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.lungcan.2019.08.002","article-title":"A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer","volume":"137","author":"Cheng","year":"2019","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2026.07.006_bib0007","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cllc.2026.07.006_bib0008","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.07.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102205","article-title":"The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non-small cell lung cancer with sensitive EGFR mutations","volume":"64","author":"Jiang","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.cllc.2026.07.006_bib0010","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.22.00051","article-title":"Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non-small-cell lung cancer: ASCO guideline rapid recommendation update","volume":"40","author":"Pisters","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2026.07.006_bib0011","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.07.006_bib0012","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.07.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101839","article-title":"Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial","volume":"57","author":"Ou","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.cllc.2026.07.006_bib0014","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jtho.2016.01.024","article-title":"The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification","volume":"11","author":"Detterbeck","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2026.07.006_bib0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMoa2212083","article-title":"Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer","volume":"388","author":"Altorki","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2026.07.006_bib0016","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society International Multidisciplinary Classification of lung adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2026.07.006_bib0017","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.cllc.2026.07.006_bib0018","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.21.01589","article-title":"Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer","volume":"40","author":"Chaft","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2026.07.006_bib0019","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"19","key":"10.1016\/j.cllc.2026.07.006_bib0020","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/djg059","article-title":"Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer","volume":"95","author":"Scagliotti","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.cllc.2026.07.006_bib0021","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/JTO.0b013e3181a5269d","article-title":"Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China","volume":"4","author":"Li","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2026.07.006_bib0022","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/JTO.0b013e3182519a42","article-title":"Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy","volume":"7","author":"Higgins","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.006_bib0023","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cllc.2026.07.006_bib0024","article-title":"Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2026.07.006_bib0025","article-title":"Computed tomography-pathology deep learning model for the precise prediction of recurrence in pathological stage IA lung adenocarcinoma","author":"Zhang","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.006_bib0026","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12957-024-03303-x","article-title":"Prognostic significance and survival benefits of postoperative adjuvant chemotherapy in patients with stage IA lung adenocarcinoma with non-predominant micropapillary components","volume":"22","author":"Li","year":"2024","journal-title":"World J Surg Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:18:42Z","timestamp":1788866322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525730426000999"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.07.006","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Efficacy and Safety of Icotinib as Adjuvant Therapy for Resected Stage IA Lung Adenocarcinoma: A Real-world Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}